These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 29614676)

  • 1. Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimer's Disease.
    Tetzloff KA; Graff-Radford J; Martin PR; Tosakulwong N; Machulda MM; Duffy JR; Clark HM; Senjem ML; Schwarz CG; Spychalla AJ; Drubach DA; Jack CR; Lowe VJ; Josephs KA; Whitwell JL
    J Alzheimers Dis; 2018; 62(4):1713-1724. PubMed ID: 29614676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau PET imaging predicts cognition in atypical variants of Alzheimer's disease.
    Phillips JS; Das SR; McMillan CT; Irwin DJ; Roll EE; Da Re F; Nasrallah IM; Wolk DA; Grossman M
    Hum Brain Mapp; 2018 Feb; 39(2):691-708. PubMed ID: 29105977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech.
    Utianski RL; Whitwell JL; Schwarz CG; Senjem ML; Tosakulwong N; Duffy JR; Clark HM; Machulda MM; Petersen RC; Jack CR; Lowe VJ; Josephs KA
    Cortex; 2018 Feb; 99():358-374. PubMed ID: 29353121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of
    La Joie R; Visani AV; Lesman-Segev OH; Baker SL; Edwards L; Iaccarino L; Soleimani-Meigooni DN; Mellinger T; Janabi M; Miller ZA; Perry DC; Pham J; Strom A; Gorno-Tempini ML; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Neurology; 2021 Feb; 96(5):e650-e661. PubMed ID: 33262228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease.
    Whitwell JL; Graff-Radford J; Tosakulwong N; Weigand SD; Machulda MM; Senjem ML; Spychalla AJ; Vemuri P; Jones DT; Drubach DA; Knopman DS; Boeve BF; Ertekin-Taner N; Petersen RC; Lowe VJ; Jack CR; Josephs KA
    Alzheimers Dement; 2018 Aug; 14(8):1005-1014. PubMed ID: 29605222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of In Vivo [18F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease.
    Xia C; Makaretz SJ; Caso C; McGinnis S; Gomperts SN; Sepulcre J; Gomez-Isla T; Hyman BT; Schultz A; Vasdev N; Johnson KA; Dickerson BC
    JAMA Neurol; 2017 Apr; 74(4):427-436. PubMed ID: 28241163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visual cognition in non-amnestic Alzheimer's disease: Relations to tau, amyloid, and cortical atrophy.
    Putcha D; Brickhouse M; Touroutoglou A; Collins JA; Quimby M; Wong B; Eldaief M; Schultz A; El Fakhri G; Johnson K; Dickerson BC; McGinnis SM
    Neuroimage Clin; 2019; 23():101889. PubMed ID: 31200149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.
    Passamonti L; Vázquez Rodríguez P; Hong YT; Allinson KS; Williamson D; Borchert RJ; Sami S; Cope TE; Bevan-Jones WR; Jones PS; Arnold R; Surendranathan A; Mak E; Su L; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
    Brain; 2017 Mar; 140(3):781-791. PubMed ID: 28122879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease.
    Sintini I; Martin PR; Graff-Radford J; Senjem ML; Schwarz CG; Machulda MM; Spychalla AJ; Drubach DA; Knopman DS; Petersen RC; Lowe VJ; Jack CR; Josephs KA; Whitwell JL
    Neuroimage Clin; 2019; 23():101823. PubMed ID: 31004914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
    Maass A; Landau S; Baker SL; Horng A; Lockhart SN; La Joie R; Rabinovici GD; Jagust WJ;
    Neuroimage; 2017 Aug; 157():448-463. PubMed ID: 28587897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy.
    Whitwell JL; Ahlskog JE; Tosakulwong N; Senjem ML; Spychalla AJ; Petersen RC; Jack CR; Lowe VJ; Josephs KA
    Parkinsonism Relat Disord; 2018 Mar; 48():3-9. PubMed ID: 29254665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease.
    Sintini I; Schwarz CG; Martin PR; Graff-Radford J; Machulda MM; Senjem ML; Reid RI; Spychalla AJ; Drubach DA; Lowe VJ; Jack CR; Josephs KA; Whitwell JL
    Hum Brain Mapp; 2019 Apr; 40(5):1618-1631. PubMed ID: 30549156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal and cross-sectional structural magnetic resonance imaging correlates of AV-1451 uptake.
    Das SR; Xie L; Wisse LEM; Ittyerah R; Tustison NJ; Dickerson BC; Yushkevich PA; Wolk DA;
    Neurobiol Aging; 2018 Jun; 66():49-58. PubMed ID: 29518752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies.
    Kantarci K; Lowe VJ; Boeve BF; Senjem ML; Tosakulwong N; Lesnick TG; Spychalla AJ; Gunter JL; Fields JA; Graff-Radford J; Ferman TJ; Jones DT; Murray ME; Knopman DS; Jack CR; Petersen RC
    Ann Neurol; 2017 Jan; 81(1):58-67. PubMed ID: 27863444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages.
    Schwarz AJ; Yu P; Miller BB; Shcherbinin S; Dickson J; Navitsky M; Joshi AD; Devous MD; Mintun MS
    Brain; 2016 May; 139(Pt 5):1539-50. PubMed ID: 26936940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
    Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
    Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer's Disease.
    Louwersheimer E; Keulen MA; Steenwijk MD; Wattjes MP; Jiskoot LC; Vrenken H; Teunissen CE; van Berckel BN; van der Flier WM; Scheltens P; van Swieten JC; Pijnenburg YA
    J Alzheimers Dis; 2016; 51(2):581-90. PubMed ID: 26890751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.